Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arthur B Epstein, Peter T Van Hoven, Alan Kaufman, Warner W Carr
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f38fcd8874054b8aa7f35084fdc2594b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f38fcd8874054b8aa7f35084fdc2594b
record_format	dspace
spelling	oai:doaj.org-article:f38fcd8874054b8aa7f35084fdc2594b2021-12-02T02:46:24ZManagement of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies1177-54671177-5483https://doaj.org/article/f38fcd8874054b8aa7f35084fdc2594b2009-04-01T00:00:00Zhttp://www.dovepress.com/management-of-allergic-conjunctivitis-an-evaluation-of-the-perceived-c-a3064https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY, USA; 4Southern California Research, Mission Viejo, CA, USAPurpose: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed.Methods: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopatadine 0.2% once daily (qd) and previous twice daily (bid) allergic conjunctivitis medications via questionnaire in allergic conjunctivitis sufferers who had previously used bid medication and then initiated olopatadine. A second conjunctival antigen challenge (CAC) study evaluated comfort of 4 allergic conjunctivitis medications. Results: Forty-nine patients from the PACE study (N = 125) with prior azelastine use were examined. Significantly more patients rated themselves &ldquo;very satisfied&rdquo; with current olopatadine use compared with past azelastine use on drop comfort (p &lt; 0.0001), speed of relief (p = 0.0004), and overall satisfaction (70% vs 16%, p &lt; 0.0001). Significantly more patients reported olopatadine &ldquo;very effective&rdquo; against swelling compared with azelastine (47% vs 8%, p = 0.0404). In the CAC study (N = 36), data from olopatadine (n = 8), azelastine (n = 9) and placebo (N = 36) groups were reported. Olopatadine was rated significantly more comfortable than azelastine upon instillation (p = 0.0223), at 30 seconds (p = 0.0479), and at 1 minute after instillation (p = 0.0240).Conclusion: In the reported studies, olopatadine 0.2% qd was more comfortable than azelastine 0.05% and preferred by patients with allergic conjunctivitis by a ratio of 4:1.Keywords: allergic conjunctivitis, azelastine, ocular allergy, olopatadine, patient perceptions Arthur B EpsteinPeter T Van HovenAlan KaufmanWarner W CarrDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 329-336 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
description	Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY, USA; 4Southern California Research, Mission Viejo, CA, USAPurpose: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed.Methods: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopatadine 0.2% once daily (qd) and previous twice daily (bid) allergic conjunctivitis medications via questionnaire in allergic conjunctivitis sufferers who had previously used bid medication and then initiated olopatadine. A second conjunctival antigen challenge (CAC) study evaluated comfort of 4 allergic conjunctivitis medications. Results: Forty-nine patients from the PACE study (N = 125) with prior azelastine use were examined. Significantly more patients rated themselves &ldquo;very satisfied&rdquo; with current olopatadine use compared with past azelastine use on drop comfort (p &lt; 0.0001), speed of relief (p = 0.0004), and overall satisfaction (70% vs 16%, p &lt; 0.0001). Significantly more patients reported olopatadine &ldquo;very effective&rdquo; against swelling compared with azelastine (47% vs 8%, p = 0.0404). In the CAC study (N = 36), data from olopatadine (n = 8), azelastine (n = 9) and placebo (N = 36) groups were reported. Olopatadine was rated significantly more comfortable than azelastine upon instillation (p = 0.0223), at 30 seconds (p = 0.0479), and at 1 minute after instillation (p = 0.0240).Conclusion: In the reported studies, olopatadine 0.2% qd was more comfortable than azelastine 0.05% and preferred by patients with allergic conjunctivitis by a ratio of 4:1.Keywords: allergic conjunctivitis, azelastine, ocular allergy, olopatadine, patient perceptions
format	article
author	Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr
author_facet	Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr
author_sort	Arthur B Epstein
title	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
title_short	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
title_full	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
title_fullStr	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
title_full_unstemmed	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
title_sort	management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/f38fcd8874054b8aa7f35084fdc2594b
work_keys_str_mv	AT arthurbepstein managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT petertvanhoven managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT alankaufman managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT warnerwcarr managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies
_version_	1718402198914727936

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Ejemplares similares